X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CardiAMP cell therapy is the first comprehensive therapeutic treatment utilizing a patient's own cells for the treatment. It is being evaluated for the treatment of chronic myocardial ischemia.
Lead Product(s): BCDA-02
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiAMP
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia’s cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application (IND) and the anticipated Phase I/II clinical development.
Lead Product(s): SCM-102
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SCM-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: StemCardia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 13, 2024
Details:
CardiAMP cell therapy is the first comprehensive therapeutic treatment utilizing a patient's own cells for the treatment. It is being evaluated in phase 3 clinical trials for the treatment of ischemic etiology heart failure of reduced ejection fraction.
Lead Product(s): BCDA-01
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiAMP
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
CardiAMP cell therapy is the first comprehensive therapeutic treatment utilizing a patient's own cells for the treatment. It is being evaluated in phase 3 clinical trials for the treatment of ischemic etiology heart failure of reduced ejection fraction.
Lead Product(s): BCDA-01
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiAMP
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
CardiALLO (Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells) is under phase 1/2 clinical development for the treatment of ischemic heart failure of reduced ejection fraction.
Lead Product(s): Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiALLO
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
BCDA-01 (CardiAMP Cell Therapy) uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.
Lead Product(s): CardiAMP Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The Company intends to use the net proceeds for advancing the Company’s investigational biotherapeutic candidates, including BCDA-01 (CardiAMP cell therapy) for the treatment of heart failure.
Lead Product(s): CardiAMP Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2023
Details:
BCDA-01 (CardiAMP Cell Therapy) uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.
Lead Product(s): CardiAMP Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
BCDA-01 (CardiAMP Cell Therapy) uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.
Lead Product(s): CardiAMP Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
BCDA-01 (CardiAMP Cell Therapy) uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.
Lead Product(s): CardiAMP Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
